Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors

Kyntra Bio announced the appointment of Andrew E. Singer, an experienced biotechnology finance executive with 25+ years in investment banking and corporate strategy, to its Board of Directors as an independent director and Audit Committee member effective October 1, 2026. Simultaneously, Maykin Ho stepped down after nearly eight years of service. Singer's appointment is expected to strengthen the company's financial position as it advances its rare disease and oncology pipeline.